Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Stryker delivered a mixed set of results for the quarter and managed to surpass Wall Street expectations on the revenue front.</li><li>The demand for the company's capital products stayed quite strong in this quarter, as viewed by the growth of double-digit of its medical division.</li><li>Also, the Instruments business experienced challenges in the supply chain mainly related to the company's capital products.</li></ul>

Stryker delivered a mixed set of results for the quarter and managed to surpass Wall Street expectations on the revenue front.The demand for the company's capital products stayed quite strong in this quarter, as viewed by the growth of double-digit of its medical division.Also, the Instruments business experienced challenges in the supply chain mainly related to the company's capital products.

Stryker Corporation: The Monterey AL Launch & Other Drivers

<ul><li>Stryker Corporation has faced a challenging macro environment and is undergoing various supply shortages but this did not stop the company from delivering a solid growth in organic sales.</li><li>Spine and orthopedics net sales also increased in the quarter in constant currency.</li><li>We prove the stock of Stryker Corporation with a ‘Hold’ rating and a revision in the target price.</li></ul>

Stryker Corporation has faced a challenging macro environment and is undergoing various supply shortages but this did not stop the company from delivering a solid growth in organic sales.Spine and orthopedics net sales also increased in the quarter in constant currency.We prove the stock of Stryker Corporation with a ‘Hold’ rating and a revision in the target price.

Stryker Corporation: The Vocera Acquisition & Other Drivers

Equity Capital Markets

<ul><li>Stryker Corporation had a decent result in the quarter and the company posted an increase in organic sales growth which was driven by double-digit growth from its Neuro-technology and MedSurg businesses.</li><li>Though the company’s implant businesses were challenged, the company’s capital products performed better than its MedSurg portfolio and Mako product technology.</li><li>Stryker had a strong performance from its more emergent businesses, which include its core trauma business, and Neurovascular gave another standout performance.</li></ul>

Stryker Corporation had a decent result in the quarter and the company posted an increase in organic sales growth which was driven by double-digit growth from its Neuro-technology and MedSurg businesses.Though the company’s implant businesses were challenged, the company’s capital products performed better than its MedSurg portfolio and Mako product technology.Stryker had a strong performance from its more emergent businesses, which include its core trauma business, and Neurovascular gave another standout performance.

Stryker Corporation: Business Strategy & Key Growth Drivers

Credit

<ul><li>Stryker Corporation’s Neurotechnology and MedSurg businesses were the major drivers of its solid organic growth in 2021.</li><li>Stryker had robust performances from its more emerging businesses, including a standout performance by Neurovascular and its core trauma business.</li><li>The international organic sales have also shown a robust growth wedged by positive sales momentum in emerging markets.</li></ul>

Stryker Corporation’s Neurotechnology and MedSurg businesses were the major drivers of its solid organic growth in 2021.Stryker had robust performances from its more emerging businesses, including a standout performance by Neurovascular and its core trauma business.The international organic sales have also shown a robust growth wedged by positive sales momentum in emerging markets.

Stryker Corporation: Detailed Credit Analysis & Financial Strength Evaluation Report

<ul><li>Stryker Corp had a decent result with a good performance in terms of organic sales.</li><li>Though its implant business diminished, the company saw the robust result for its capital products and Mako product technology over its MedSurg portfolio.</li><li>Stryker had robust performances from its more emerging businesses, including a standout performance by Neurovascular and its core trauma business.</li></ul>

Stryker Corp had a decent result with a good performance in terms of organic sales.Though its implant business diminished, the company saw the robust result for its capital products and Mako product technology over its MedSurg portfolio.Stryker had robust performances from its more emerging businesses, including a standout performance by Neurovascular and its core trauma business.

Stryker Corporation: Financial & Price Forecasts

United States

Stryker Corporation develops, manufactures, and markets specialty surgical and medical products.  The Company's products include implants, biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Stryker Corp (SYK US)

Stryker Corporation: The Monterey AL Launch & Other Drivers

Stryker delivered a mixed set of results for the quarter and managed to surpass Wall Street expectations on the revenue front. The demand for the...

Baptista Research

Stryker Corporation: The Vocera Acquisition & Other Drivers

Stryker Corporation has faced a challenging macro environment and is undergoing various supply shortages but this did not stop the company from...

Baptista Research

Stryker Corporation: Business Strategy & Key Growth Drivers

Stryker Corporation had a decent result in the quarter and the company posted an increase in organic sales growth which was driven by double-digit...

Baptista Research

Stryker Corporation: Detailed Credit Analysis & Financial Strength Evaluation Report

Stryker Corporation’s Neurotechnology and MedSurg businesses were the major drivers of its solid organic growth in 2021. Stryker had robust...

Baptista Research

Stryker Corporation: Financial & Price Forecasts

Stryker Corp had a decent result with a good performance in terms of organic sales. Though its implant business diminished, the company saw the...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)